1 completed, 1 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Resectable: new trials by email Literature Review of Resectable trials Research Report on Resectable
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma Pembrolizumab, Gemcitabine, Cisplatin - Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Amsterdam UMC, location VUmc | 150 | 2026-04-17 | 2026-08-25 |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage | Phase 2 | Completed | MedImmune LLC | 84 | 2019-03-08 | 2022-02-24 |
Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Klatskin Tumor (1) · Neoplasms (1)
Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Cisplatin (1) · Gemcitabine (1) · danvatirsen (1) · durvalumab (1) · monalizumab (1) · pembrolizumab (1)
Amsterdam UMC, location VUmc (1) · MedImmune LLC (1)
Canada (1) · France (1) · Italy (1) · Netherlands (1) · Portugal (1) · Spain (1) · Switzerland (1) · United States (1)